Skip to content

To study the irritant and allergic potential of test products in Men and Women.

Human Repeat Insult Patch Test (HRIPT) IS 4011:2018 Guidelines. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/02/062215
Enrollment
220
Registered
2024-02-01
Start date
Unknown
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Cold relief Roll on: Approximately 0.04 ml of Cold Relief Roll on will be applied on marked test sites and semi-occluded with the help of gauze for a duration of 24 hours. A total of 9

Sponsors

Zydus Lifesciences Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Voluntary men and or women between 18 and 65 years with 50 participants having sensitive skin as determined by lactic acid sting test. 2. Photo type III to V. 3. Having apparently healthy skin on test area. 4. For whom the Investigator considers that the compliance will be correct. 5. Cooperating, informed of the need and duration of the examinations, and ready to comply with protocol procedures. 6. Willing to give written informed consent to participate in the trial after informing all information concerning the trial procedures and trial objectives. 7. Willingness to avoid intense UV exposure on test site (sun or artificial UV), during the course of the trial. 8. Willingness to avoid water contact (i.e.: swimming) or activity which cause sweating (i.e.: exercise, sauna...), during the course of the trial. 9. Should be able to read and write (in English, Hindi, or local language). 10. Having valid proof of identity and age.

Exclusion criteria

Exclusion criteria: 1. Pregnancy (by UPT) and lactating women. 2. Scars, excessive terminal hair, or tattoo on the studied area. 3. A participant who the Investigator feels will not be compliant with trial requirements. 4. Dermatological infection or pathology on the level of studied area. 5. Hypersensitivity, allergy antecedent (to any cosmetic product, raw material, hair dye). 6. Any clinically significant systemic or cutaneous disease, which may interfere with trial procedures. 7. Chronic illness which may influence the outcome of the trial. 8. Participants on any medical treatment either systemic or topical which may interfere with the performance of the trial (presently or in the past 1 month). 9. Participant in an exclusion period or participating in another food, cosmetic or therapeutic trial.

Design outcomes

Primary

MeasureTime frame
Evaluation of cutaneous tolerance by dermatological scoring.Timepoint: Visit 1: ICD and inclusion or exclusion. Induction Phase: Patch application on Visit 1 (V1, V3,V5, V7, V9, V11, V13, V15, V17). Patch will be removed on Visit 2 (V2, V4, V6, V8, V10, V12,V14, V16, V18). Patch area will be clinically examined, graded and scored on Visit 3 (V3, V5, V7, V9, V11, V13, V15, V17, V19) Challenge Phase: Patch application will be on naïve sites on the back on V20; patch will be removed at V21 (24 hours).Scoring on V22 (48 hours), V23 (72 hours). V24 (96 hours).

Secondary

MeasureTime frame
NoneTimepoint: None

Countries

India

Contacts

Public ContactMs Preetha Paul

C.L.A.I.M.S. Pvt. Ltd.

preetha@claimsclinical.com66758851

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026